a si li kang yu ji fei ti ni

..............page:125

xun zheng yi xue za zhi zheng gao zheng ding tong zhi

..............page:66

Could Lung Cancer Patients without Accurate Pathological Diagnosis Get the Anticancer Treatment?
chen zhen dong ; song xiang qun ; hu cheng ping ; han bao hui

..............page:126-128

NCCN Fever and Neutropenia Practice Guidelines
CHU Qian;YU Shi-ying

..............page:113-125

Principles for International Registration of Protocol Information and Results from Human Trials of Health-related Interventions-The Ottawa Statement, Part One
LIU Jian-ping;ZHANG Jing;CHEN Jun-chao

..............page:109-112

Brief Introduction to Common Bias of Systematic Reviews
ZHANG Qian;XUE Qian

..............page:105-108

Tadalafil for Erectile Dysfunction:a Systematic Review of Randomized Trials
REN Ming-liang;JIANG Jun;LAN Wei-hua

..............page:101-104

The Prevalence and Clinical Features of Inpatients with Diabetes
YANG Hua-zhang;KUANG Jian;YU Gui-fang;LIU Li-hong;PEI Jian-hao;CHEN Zhong;CHEN Hong-mei;CHEN Liang;LI Zhong-wen;WU Ying;HE Peng-cheng;LI Juan;HUANG Xiao-ying

..............page:97-100

Terbinafine in Fungal Infections of the Nails:a Meta-analysis of Randomized Double-blind Clinical Trials
WANG Qun;HAN Yong-zhi

..............page:93-96

Results of Two Open-label, Multicenter Phase Ⅱ Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER-2 Positive Advanced Breast Cancer
JIANG Ze-fei;ZHENG Deng-yun

..............page:90-92

Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel,with or without Trastuzumab in Breast Cancer
XU Bing-he;LIN Xue-ting

..............page:87-89

Significantly Higher Pathologic Complete Remission Rate after Neoadjuvant Therapy with Trastuzumab, Paclitaxel,and Epirubicin Chemotherapy
SHEN Kun-wei;LIAO Ning

..............page:84-86

Evaluation on Parallel HER-2 Testing of Both FISH and Immunohistochemistry in Breast Cancer Tissues
LIU Yan-hui;ZHANG Guo-chun

..............page:81-83

Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination with Paclitaxel for the Treatment of HER-2 Positive Metastatic Breast Carcinome
WANG Shen-ming;YIN Heng-hui;LI Xue-rui

..............page:77-80

Trastuzumab Plus Adjuvant Chemotherapy Improves Survival of Operable HER-2 Positive Breast Cancer
RAO Nan-yan;SHAO Zhi-min;WANG Kun

..............page:74-76,80

American Society of Clinical Oncology Annual Report--Clinical Cancer Advances 2005
DONG Song;ZHU Jian-quan;WU Yi-long

..............page:67-73

Major Advances in Clinical Oncology 2005
WU Yi-long

..............page:65-66